Post Marketing Survey of Vesicare in Japan

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is to evaluate the effect of Vesicare on quality of life (QOL) in female patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Solifenacin Succinate

Criteria

Inclusion Criteria:

• Previously untreated OAB patients

• Patients who meet the diagnostic criteria for OAB provided in the clinical guidelines for overactive bladder (patients who have urinary urgency at least once weekly as an essential symptom and at least one of the other OAB symptoms including daytime frequency, nighttime frequency, and urgency incontinence)

• Patients who can understand and answer OAB-q (Japanese version)

• Patients from whom data on all items concerning OABSS, OAB-q, and satisfaction score for urination can be obtained at baseline

• Patients who are expected to be treated for at least 12 weeks